Liquidia Technologies, Inc. (NASDAQ:LQDA) Insider Sells $68,501.16 in Stock

Liquidia Technologies, Inc. (NASDAQ:LQDA - Get Free Report) insider Scott Moomaw sold 4,797 shares of the company's stock in a transaction on Monday, July 14th. The stock was sold at an average price of $14.28, for a total transaction of $68,501.16. Following the completion of the transaction, the insider owned 223,231 shares of the company's stock, valued at $3,187,738.68. This trade represents a 2.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Liquidia Technologies Stock Performance

NASDAQ LQDA traded down $0.20 during trading hours on Friday, hitting $14.41. 929,859 shares of the company's stock traded hands, compared to its average volume of 1,301,913. The business's fifty day moving average price is $14.88 and its two-hundred day moving average price is $14.48. The company has a current ratio of 2.93, a quick ratio of 2.91 and a debt-to-equity ratio of 2.08. The firm has a market capitalization of $1.23 billion, a P/E ratio of -9.14 and a beta of -0.01. Liquidia Technologies, Inc. has a 52 week low of $8.26 and a 52 week high of $19.41.

Liquidia Technologies (NASDAQ:LQDA - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.03). The firm had revenue of $3.12 million during the quarter, compared to the consensus estimate of $3.23 million. Liquidia Technologies had a negative return on equity of 177.91% and a negative net margin of 903.80%. Equities research analysts predict that Liquidia Technologies, Inc. will post -1.51 EPS for the current year.

Hedge Funds Weigh In On Liquidia Technologies

A number of hedge funds have recently modified their holdings of the company. Hurley Capital LLC bought a new position in shares of Liquidia Technologies during the first quarter worth $32,000. GAMMA Investing LLC boosted its position in shares of Liquidia Technologies by 65.6% during the first quarter. GAMMA Investing LLC now owns 2,961 shares of the company's stock worth $44,000 after acquiring an additional 1,173 shares during the last quarter. Steward Partners Investment Advisory LLC bought a new position in shares of Liquidia Technologies during the fourth quarter worth $59,000. Summit Investment Advisors Inc. boosted its position in shares of Liquidia Technologies by 35.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company's stock worth $78,000 after acquiring an additional 1,719 shares during the last quarter. Finally, Quarry LP bought a new position in shares of Liquidia Technologies during the first quarter worth $79,000. 64.54% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

LQDA has been the topic of several recent analyst reports. Scotiabank increased their price objective on shares of Liquidia Technologies from $36.00 to $37.00 and gave the company a "sector outperform" rating in a research report on Wednesday, May 28th. Needham & Company LLC restated a "buy" rating on shares of Liquidia Technologies in a research note on Monday, June 2nd. BTIG Research restated a "buy" rating on shares of Liquidia Technologies in a research note on Tuesday, May 27th. Oppenheimer set a $13.00 price objective on shares of Liquidia Technologies and gave the company an "underperform" rating in a research note on Monday, May 19th. Finally, Wells Fargo & Company raised their price objective on shares of Liquidia Technologies from $23.00 to $25.00 and gave the company an "overweight" rating in a research note on Thursday, June 12th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $26.89.

Liquidia Technologies Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).